Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Wells Fargo Initiates Oxigene


Wells Fargo initiates Oxigene Inc. (OXGN) coverage with buy.

Analyst Paul Keough believes Oxigene's approach to vessel disruption, called vascular targeting agents (VTAs), has breakthrough potential in numerous cancer indications as a complementary add-on treatment to chemotherapy, radiation therapy, and anti-angiogenesis agents.

He believes Oxigene leads the clinical race for VTAs, which could eventually gain widespread use in large cancer markets.

Likely as partnership, Keough estimates the company could have sales potential of $1 billion to $2 billion. He has a $7 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus